Abstract

This is the final report of the SETTREND project which received funding under the Seventh Framework Programme (FP7). The aim of the project was to develop new drug leads for the treatment of schistosomiasis. The report begins by outlining the need for new drugs to combat schistosomiasis. It then describes the holistic approach that enabled the researchers to progress from the cloned target protein, via structural analysis, in silico and high-throughput screening, to the identification of new lead compounds validated by their toxicity for the parasite in vitro and in vivo. The project has fulfilled its principal objectives and has supplied a large number of HME inhibitors with novel structures that are active against the parasite as well as producing a significant number of publications and communications.